

| | |
|-----------------------|--|
| Cat. No: | MAB-10166 |
| Size: | 100 µg |
| Clone: | Bp53.12 |
| Concentration: | 1mg/ml |
| Host: | Ms |
| Isotype: | IgG2a |
| Immunogen: | Bacterially expressed full-length wild-type p53 |
| Reactivity: | Hu Flow Cytometry Immunoprecipitation Western Blotting Recommended dilution: 1-2 µg/ml, overnight in 4°C Positive control: RAMOS human lymphoma cell line Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold Lysis buffer (1% laurylmaltoside in 20 mM Tris/Cl, 100 mM NaCl pH 8.2, 50 mM NaF including Protease inhibitor Cocktail). Incubate 60 min on ice. Centrifuge to remove cell debris. Mix lysate with non-reducing SDS-PAGE sample buffer. |
| Applications: | Application note: Non-reducing conditions. SDS-PAGE (12% separating gel). Immunohistochemistry (paraffin sections) Immunocytochemistry: 2-10µg/ml ELISA |
| Purification: | Purified from ascites by precipitation methods |
| Background: | The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nucleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. The antibody BP53-12 recognizes defined epitope (aa 16-25) on human p53, a 50 kDa tumour suppressor found in increased amounts in a wide variety of transformed cells; it is frequently mutated or inactivated in many types of cancer. |
| Form: | Liquid |
| Buffer: | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.5 |
| Storage: | Store at 2-8°C. Do not freeze. |

References

*Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. *Oncogene*. 1991 Sep;6(9):1699-703. [Abstract]

*Bartkova J, Bartek J, Lukas J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Midgley CA, Lane DP: p53 protein alterations in

human testicular cancer including pre-invasive intratubular germ-cell neoplasia. *Int J Cancer*. 1991 Sep 9;49(2):196-202. [Abstract]

*Dolezalova H, Vojtesek B, Kovarik J: Epitope analysis of the human p53 tumour suppressor protein. *Folia Biol (Praha)*. 1997;43(1):49-51. [Abstract]

Rössner P Jr, Binková B, Chvátalová I, Srám RJ: Acrylonitrile exposure: the effect on p53 and p21(WAF1) protein levels in the blood plasma of occupationally exposed workers and in vitro in human diploid lung fibroblasts. *Mutat Res*. 2002 May 27;517(1-2):239-50

**For Research use only
IMMUNOLOGICAL SCIENCES**